Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03475693 · ClinicalTrials.gov registry record · Early Phase 1
A Cohort Study Evaluating the Efficacy of PO Magnesium in the Treatment of Acute Traumatic Brain Injury in Adolescents
A Early Phase 1 study of Concussion Post Syndrome, sponsored by Corewell Health South.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT03475693: Completed Early Phase 1 study of Concussion Post Syndrome, sponsored by Corewell Health South.
NCT03475693 is a Early Phase 1 study of Concussion Post Syndrome that has completed, run by Corewell Health South. The registered enrollment target is 17 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03475693, a Early Phase 1 study of Concussion Post Syndrome, has completed, sponsored by Corewell Health South.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the efficacy of magnesium in symptomatic reduction of mild traumatic brain injury in the adolescent population in the acute setting of injury.
Primary Outcome
Using post concussion symptom severity scores, the patient will complete symptom severity scores at specified intervals for comparison in post concussion severity score reduction. Higher scores indicate more severe symptoms, and lower scores indicate less severe symptoms.Post-Concussion Symptom Checklist Rating Mild Mod. Severe Initial 1 Hr. 48 Hr. 120 Hr. Headache 0-6 Nausea 0-6 Vomiting 0-6 Balance Problems 0-6 Dizziness 0-6 Visual Problems 0-6 Fatigue 0-6 Sensitivity to light 0-6 Sensitivity
Conditions Studied
Interventions
- DRUG Acetaminophen
- DRUG Magnesium Oxide
- DRUG Zofran ODT 4 MG Disintegrating Oral Tablet
Study Locations (1)
Michigan
- Lakeland Regional Healthcare - Saint Joseph
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2019-12-30 |
| Phase | Early Phase 1 |
What the finished NCT03475693 record still lists
NCT03475693 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Concussion Post Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Acetaminophen is the first listed.
NCT03475693 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT03475693 about?
NCT03475693 is a clinical study titled "A Cohort Study Evaluating the Efficacy of PO Magnesium in the Treatment of Acute Traumatic Brain Injury in Adolescents". The objective of this study is to evaluate the efficacy of magnesium in symptomatic reduction of mild traumatic brain injury in the adolescent population in the acute setting of injury.
What is the current status of trial NCT03475693?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 17 participants. The study started on 2017-09-01. Estimated completion is 2019-12-30.
What conditions does trial NCT03475693 study?
This clinical trial studies the following conditions: Concussion Post Syndrome.
What interventions are being tested in trial NCT03475693?
The interventions under investigation include: Acetaminophen (DRUG), Magnesium Oxide (DRUG), Zofran ODT 4 MG Disintegrating Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT03475693?
This trial is sponsored by Corewell Health South, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03475693 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03475693's enrollment target sits among peer trials
17 1351st of 2000 higher than 632 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI